Skip to content
Companies

BioCytics

Autologous immune cell therapy for solid tumors

Raised to date

$25K

of $7M offered across 1 Form D filing

Still open
$7M
Investors
1
Last filed
Mar 13, 2026

About

Biocytics is a biotechnology company specializing in the development of personalized cellular immunotherapies for cancer. It primarily focuses on autologous adaptive cell therapy (AACT) to treat solid tumors using a patient's own immune cells, while also operating as a contract development and manufacturing organization (CDMO) and contract research organization (CRO) for other early-phase cellular therapy firms.

The company leverages an integrated model that combines its own therapeutic development with a full suite of services including a CDMO, CRO, and a BioBank. Its therapeutic platform is distinguished by a point-of-care manufacturing process for non-genetically modified effector cells.

Funding

  • Option to acquireFiled Mar 13, 2026Form D
    $25K/ $7M

Product

Personalized Cellular Immunotherapies (AACT)

Cellular Immunotherapy

Biocytics develops autologous immune cellular therapies, such as its IND-bound BCyIF1 immune cell fractions, which are currently at the preclinical stage. This approach uses a patient's own reinvigorated immune cells, including γδ T-cells and other T-cells, to target and treat solid tumors without genetic modification.

  • Utilizes patient's own immune cells (autologous)
  • Focuses on non-genetically modified effector cells
  • Employs a point-of-care manufacturing process

Built for

The primary customer segments are healthcare and biotechnology firms that require specialized CDMO/CRO services for early-phase cellular therapy development. The ultimate end-users for its proprietary therapies are patients diagnosed with solid tumors.

People on file